Besides, an augmented ADAM-17 during SARS-CoV-2 infection activates the release of pro-inflammatory cytokines, including IL-6 and TNF-α, which are correlated with a higher risk of ARDS and ALI (40). Here, ADAM17 is linked to acute respiratory distress syndrome.